Dr. Gerrina Ruiter discusses zongertinib's promising efficacy in treating HER2-mutant NSCLC, highlighting its unique effectiveness against brain metastases.

Gerrina Ruiter, MD, PhD, highlights the Beamion LUNG-1 study's impact on treating HER2-mutant non-small cell lung cancer with ...

Belantamab mafodotin (Blenrep), pomalidomide (Pomalyst), and dexamethasone (BPd) was well tolerated and led to deep responses in patients with high-risk multiple myeloma.

The 2025 ESMO Congress will highlight practice-changing late-breaking abstracts in gastrointestinal malignancies, including ...

The ESMO 2025 Congress will highlight late-breaking abstracts on RCC and bladder cancer, focusing on immune checkpoint ...

Cancer care for younger adults emphasizes emotional well-being and multidisciplinary support, transforming treatment ...

Cevostamab showed a 93% MRD-negative complete response rate at 1 year post CAR T-cell therapy in heavily pretreated multiple myeloma patients. Cevostamab delivered feasible and well-tolerated ...

David Chism, MD: For pairing it with the immunotherapy, I would prefer just 1 chemotherapy rather than ...

Shane Dormady, MD, discusses the unique emotional care needs of young adults with cancer, emphasizing hope and holistic ...

AMXT 1501 is a novel polyamine transport inhibitor designed to block the uptake of polyamines, therefore working to stop the growth and survival of tumors. DFMO is an irreversible inhibitor of ...

Chandler H. Park, MD, a medical oncologist at Norton Cancer Institute and advisory dean/professor at University of Louisville in Kentucky, discusses the Category 1 treatment options for metastatic ...

Post-CAR T infection prophylaxis should follow European Hematology Association/European Society for Blood and Marrow ...